<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409459</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT14038</org_study_id>
    <nct_id>NCT02409459</nct_id>
  </id_info>
  <brief_title>Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia</brief_title>
  <official_title>A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of
      iron deficient patients with fibromyalgia. Eligible subjects will be randomized in a 1:1
      ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed
      for efficacy and safety for 42 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded, randomized, placebo-controlled study. All subjects who meet the inclusion
      requirements and no exclusion criteria will be entered into an up to 14 day screening phase.
      Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days
      0 and 5. All treated subjects will be followed for efficacy and safety for 42 days. Subjects
      will visit the clinic on days 0 and 5 for treatment, and then on days 14, 28, and 42. The
      subject's participation in the study will be for approximately 42 days from day 0.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With a ≥13 Point Improvement in FIQR Score</measure>
    <time_frame>Day 42</time_frame>
    <description>The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BPI, Pain Interference</measure>
    <time_frame>Change from Baseline in Brief Pain Inventory Pain Interference Score at Day 42</time_frame>
    <description>The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FIQR Score</measure>
    <time_frame>Change from Baseline in FIQR score at Day 42</time_frame>
    <description>The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BPI, Pain Severity</measure>
    <time_frame>Change from Baseline in Brief Pain Inventory Pain Severity Score at Day 42</time_frame>
    <description>The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fatigue Visual Numeric Scale</measure>
    <time_frame>Change from Baseline in Fatigue Visual Numeric Scale at Day 42</time_frame>
    <description>Scores range from 0 to 10, with the higher score indicating more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Iron Indices, Serum Ferritin</measure>
    <time_frame>Change from Baseline in Iron Indices, Serum ferritin at Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Iron Indices - Transferrin Saturation</measure>
    <time_frame>Change from baseline in Iron Indices, Transferrin saturation, at Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Iron Deficiency</condition>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Injectafer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 cc of Normal Saline IV push at 2 ml/minute</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectafer</intervention_name>
    <arm_group_label>Injectafer</arm_group_label>
    <other_name>Ferric Carboxymaltose (FCM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject's ≥ 18 years of age, able to give informed consent to the
             study.

          -  Fibromyalgia diagnosis based on The 2011 modification of the American College of
             Rheumatology (ACR) 's 2010 preliminary criteria for diagnosing fibromyalgia
             (2011ModCr)

          -  A baseline score ≥ 60 on the FIQR

          -  Subject's current medications to treat fibromyalgia, including pain medicines,
             anti-depressants, sleep medications must be on a stable dose for at least 30 days.

          -  Subject's current narcotic medication must be on a stable dose for at least 30 days
             prior to randomization

          -  Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be
             practicing an acceptable form of birth control: have had a hysterectomy or tubal
             ligation, or otherwise be incapable of pregnancy, or have practiced any of the
             following methods of contraception for at least one month prior to study entry:
             hormonal contraceptives, spermicide and barrier, intrauterine device, partner
             sterility.

        Exclusion Criteria:

          -  Parenteral iron use within 4 weeks prior to screening.

          -  History of &gt; 10 blood transfusions in the past 2 years.

          -  Anticipated need for blood transfusion during the study.

          -  Known hypersensitivity reaction to any component of Injectafer® (Ferric
             Carboxymaltose).

          -  Current or acute or chronic infection other than viral upper respiratory tract
             infection

          -  Malignancy (other than basal or squamous cell skin cancer or the subject has been
             cancer free for ≥ 5 years).

          -  Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).

          -  Pregnant or lactating women.

          -  Severe peripheral vascular disease with significant skin changes.

          -  Seizure disorder currently being treated with medication.

          -  Baseline ferritin ≥ 50 ng/mL.

          -  Baseline TSAT ≥ 20%.

          -  History of hemochromatosis or hemosiderosis or other iron storage disorders.

          -  Known positive hepatitis with evidence of active disease.

          -  Hemoglobin greater than the upper limit of normal.

          -  Calcium or phosphorous outside the normal range.

          -  Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with
             evidence of active hepatitis (i.e., AST/ALT greater than the upper limit of normal).

          -  Known positive HIV-1/HIV-2 antibodies (anti-HIV)

          -  Received an investigational drug within 30 days before randomization.

          -  Chronic alcohol or drug abuse within the past 6 months.

          -  Any other pre-existing laboratory abnormality, medical condition or disease which in
             view of the investigator participation in this study may put the subject at risk.

          -  Subject unable to comply with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Falone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Luitpold Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>November 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Injectafer</title>
          <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Group B: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Injectafer</title>
          <description>Group A: Injectafer</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="10.85"/>
                    <measurement group_id="B2" value="41" spread="11.07"/>
                    <measurement group_id="B3" value="43" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of iron intolerance</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of drug allergy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IRLS score per Arm/Group</title>
          <description>‘International Restless Legs Syndrome Study Group Rating Scale’ (IRLS) The IRLS is composed of 10 items. It gives a global score for all 10 items that is most commonly used as an overall severity score. 9 of the 10 items investigate two dimensions of the RLS severity. Item 3 is part of the diagnostic criteria and does not belong to any of the two dimensions. It is used for the total score for overall RLS severity.
Symptom severity subscale: 0-24 Impact on daily living subscale: 0-12 Global score: 0-40 For all scores, higher score = higher symptom impact.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.3" spread="14.9"/>
                    <measurement group_id="B2" value="13.4" spread="13.16"/>
                    <measurement group_id="B3" value="14.8" spread="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With a ≥13 Point Improvement in FIQR Score</title>
        <description>The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.</description>
        <time_frame>Day 42</time_frame>
        <population>The Safety population consisted of all subjects who received at least one dose of randomized treatment. The Efficacy Evaluable Population consisted of all subjects who received at least 1 dose of randomized treatment with at least 1 completed post treatment FIQR evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a ≥13 Point Improvement in FIQR Score</title>
          <description>The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.</description>
          <population>The Safety population consisted of all subjects who received at least one dose of randomized treatment. The Efficacy Evaluable Population consisted of all subjects who received at least 1 dose of randomized treatment with at least 1 completed post treatment FIQR evaluation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BPI, Pain Interference</title>
        <description>The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0–10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.</description>
        <time_frame>Change from Baseline in Brief Pain Inventory Pain Interference Score at Day 42</time_frame>
        <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BPI, Pain Interference</title>
          <description>The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0–10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.</description>
          <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="3.3"/>
                    <measurement group_id="O2" value="-2.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FIQR Score</title>
        <description>The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.</description>
        <time_frame>Change from Baseline in FIQR score at Day 42</time_frame>
        <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FIQR Score</title>
          <description>The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.</description>
          <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.0" spread="29.5"/>
                    <measurement group_id="O2" value="-29.7" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BPI, Pain Severity</title>
        <description>The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0–10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.</description>
        <time_frame>Change from Baseline in Brief Pain Inventory Pain Severity Score at Day 42</time_frame>
        <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BPI, Pain Severity</title>
          <description>The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0–10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.</description>
          <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="2.7"/>
                    <measurement group_id="O2" value="-1.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fatigue Visual Numeric Scale</title>
        <description>Scores range from 0 to 10, with the higher score indicating more fatigue.</description>
        <time_frame>Change from Baseline in Fatigue Visual Numeric Scale at Day 42</time_frame>
        <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fatigue Visual Numeric Scale</title>
          <description>Scores range from 0 to 10, with the higher score indicating more fatigue.</description>
          <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="3.2"/>
                    <measurement group_id="O2" value="-1.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Iron Indices, Serum Ferritin</title>
        <time_frame>Change from Baseline in Iron Indices, Serum ferritin at Day 42</time_frame>
        <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Iron Indices, Serum Ferritin</title>
          <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.5" spread="145.9"/>
                    <measurement group_id="O2" value="2.0" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Iron Indices - Transferrin Saturation</title>
        <time_frame>Change from baseline in Iron Indices, Transferrin saturation, at Day 42</time_frame>
        <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 cc of Normal Saline IV push at 2 ml/minute
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Iron Indices - Transferrin Saturation</title>
          <population>Patients without a particular measure at a required time point were excluded from the analysis of that measure.</population>
          <units>percent of transferrin saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="11.4"/>
                    <measurement group_id="O2" value="5.8" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Injectafer</title>
          <description>15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Injectafer</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>15 cc of Normal Saline IV push at 2 ml/minute
Placebo: Normal saline solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Falone, MD</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>610.650.4200 ext 844</phone>
      <email>mfalone@luitpold.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

